TeamDrive
RUS

RMI Partners

www.rmivc.com

RMI Patners - a pharmaceutical project management company with a focus on investments to out of the box developments in medical, pharmaceutical and biotechnology sectors worldwide.

The company’s key mission – to develop and introduce innovative drugs and medical equipment into the market and to create world-class Russian domiciled expertise in Life Sciences venture financing.

Leonid Melamed"It is strategically important that Russian developers of innovative pharmaceuticals appear large in number. Three or thirty companies of this kind in place will not resolve the problem. In the Silicon valley - there are tens of thousands of them, therefore the probability of success is rather high. Drug development industry is alive only if millions of people are dealing with it consolidated in tens of thousands of companies. To make this happen at our place, people with good ideas should be aware of how to become an accurate applicant, and also there must be institutions willing to invest and perform a function of business angels".

Media Center

  • 19 September 2018

    Russia approves new state strategy for pharmaceutical industry

    A new state strategy for the development of the domestic pharmaceutical industry, known as "Strategy for the development of the pharmaceutical industry of Russia until 2030," has been recently approved by the Russian Ministry of Industry and Trade, with the aim to bring the Russian pharmaceutical production to a new level.

  • 18 September 2018

    The Ministry of Health of the Russian Federation improves patent protection law

    The Ministry of Health of Russia has published a notification on the development of amendments to Federal Law No. 61 of 12.04.2010 “On circulation of medicinal products”, designed to synchronize it with regulatory acts of the Eurasian Economic Union. The procedure for registration of the medicinal product will be corrected.

  • 17 September 2018

    GlobalData published new report on the Top 25 pharma companies

    The performance highlights of the Top 25 publicly traded global pharmaceutical companies by Market Cap (Mcap) for the quarter ended June 30, 2018 (Q2), compared to the quarter ended March 31, 2018 (Q1), have been analyzed in the latest research from GlobalData, a leading data and analytics company.

  • 14 September 2018

    US scientists conduct clinical trial of influenza vaccine with imiquimod

    A Phase 1 clinical trial examining whether a topical cream can enhance the immune response conferred by a “pre-pandemic” influenza vaccine is underway at Baylor College of Medicine in Houston (USA). Investigators are evaluating whether imiquimod cream, which is commonly used to treat genital warts and certain skin cancers, can boost the body’s immune response to an H5N1 influenza vaccine. The trial is enrolling 50 healthy adults ages 18-50 years. 

Read more